Compare Dyne Therapeutics Inc. Common Stock (DYN) vs FormFactor Inc. FormFactor Inc. Common Stock (FORM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs FormFactor Inc. FormFactor Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while FormFactor Inc. FormFactor Inc. Common Stock trades at $115.55 (market cap $10.01B). The key difference: FormFactor Inc. FormFactor Inc. Common Stock is far larger — about 3.5× Dyne Therapeutics Inc. Common Stock's market cap, and FormFactor Inc. FormFactor Inc. Common Stock is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and FormFactor Inc. FormFactor Inc. Common Stock for 6 Days on average.
| DYN | FORM | |
|---|---|---|
Market Cap | $2.86B | $10.01B |
Volume | 3,341,579 | 1,445,909 |
Sector | Health | Technology |
52-Week High | $26.78 | $159.93 |
52-Week Low | $14.60 | $41.29 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $9.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FormFactor (FORM) trades at $128.09, down 1.68% on the day, amid a bullish technical setup with key support at $127. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28. Revenue and net income are projected to grow significantly in 2026, though valuation ratios remain elevated.
The outlook is positive, driven by strong AI-driven semiconductor demand and strategic collaborations, but high P/E and P/S ratios pose valuation risks. Analyst consensus is bullish with a $154.71 price target, though insider selling and negative cash flow in 2025 warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About FormFactor Inc. FormFactor Inc. Common Stock
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →
